Business Context and Reporting Period
This Form 8-K is a current report filed by Indivior Pharmaceuticals, Inc. (Indivior) on September 16, 2026. The filing discloses a significant corporate event: the declaration of a special cash dividend in connection with a previously announced merger agreement with Supernus Pharmaceuticals, Inc. (Supernus), entered into on August 1, 2026.
Key Financial Metrics and Transaction Details
- Special Dividend Amount: $8.13 per share of Indivior common stock.
- Dividend Record Date: October 30, 2026.
- Anticipated Payment Date: On or about November 6, 2026, contingent on the closing of the Merger.
- Equity Awards: $8.13 per share underlying Indivior equity awards will be payable upon vesting to eligible award holders.
- Merger Closing Expectation: On or about November 2, 2026.
- Financial Metrics: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Conditions
The primary material change is the declaration of the Special Dividend, which is strictly conditioned upon the successful closing of the Merger. Supernus stockholders will not receive the Special Dividend on any Indivior shares received as merger consideration. The filing notes that Indivior expects at least a majority of the Special Dividend to exceed its current and accumulated earnings and profits. Consequently, the distribution may be treated as a return of capital to the extent of a U.S. holder's basis in the stock, followed by capital gain treatment.
Outlook, Risks, and Management Commentary
Management anticipates the Merger will close on November 2, 2026, subject to stockholder approvals from both Indivior and Supernus, regulatory approvals, and the satisfaction of other closing conditions. The filing includes extensive forward-looking statements regarding the transaction's completion and the combined company's prospects.
Key Risks Identified:
- Failure to obtain required stockholder or regulatory approvals.
- Delays in closing or failure to consummate the merger.
- Impact of additional indebtedness incurred to fund the Special Dividend on the combined company.
- Business disruption and diversion of management attention.
- Failure to realize anticipated synergies or cost savings.
- Macroeconomic factors, including economic downturns and international conflicts.
Investor Verification Checklist
- Verify the status of stockholder approvals for both Indivior and Supernus required to close the Merger.
- Confirm the final tax treatment of the Special Dividend (return of capital vs. capital gain) based on individual cost basis.
- Review the joint proxy statement/prospectus filed on September 11, 2026, for detailed financial terms and risk factors.
- Monitor regulatory approval status and any potential competing acquisition proposals.
- Assess the impact of the Special Dividend funding on the combined entity's future liquidity and debt load.